Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Mekinist in Advanced KRAS-Mutant NSCLC
NCT03299088Phase 1Completed
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab and trametinib in non-small cell lung cancer (NSCLC). Started Jun 2018; status: completed.
02
Drugs
pembrolizumabtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03299088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299088.